As of September 30, 2026, SynAct Pharma AB carries a market capitalization of 86.69M, placing it among publicly traded companies globally. Its enterprise value stands at 86.96M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 86.69M |
| Enterprise Value | 86.96M |
SynAct Pharma AB's next confirmed earnings release is scheduled for February 18, 2027.
| Earnings Date | 2/18/2027 |
As of September 30, 2026, SynAct Pharma AB has 56.00M shares outstanding.
| Shares Outstanding | 56.00M |
These figures are as of September 30, 2026.
| PB Ratio | 6.92 |
| P/TBV Ratio | -42.70 |
| P/FCF Ratio | -8.73 |
| P/OCF Ratio | -8.73 |
As of September 30, 2026, SynAct Pharma AB maintains a current ratio of 4.79, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 4.79 |
| Quick Ratio | 3.29 |
| Debt / Equity | 32.08 |
| Debt / EBITDA | -0.42 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.
| Employee Count | 8.00 |
Over the twelve months ended September 30, 2026, SynAct Pharma AB recorded an income tax benefit of -704,693.71 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -9.76M and -9.05M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -704,693.71 |
These figures are as of the close on November 17, 2026.
| 50-Day Moving Average | 1.52 |
Over the twelve months ended September 30, 2026, SynAct Pharma AB generated - - in revenue and converted that into -9.05M in net income, yielding earnings per share of -0.17. EBITDA reached -9.52M, while operating income came in at -9.52M.
| Operating Income | -9.52M |
| Pretax Income | -9.76M |
| Net Income | -9.05M |
| EBITDA | -9.52M |
| EBIT | -9.52M |
| Earnings Per Share (EPS) | -0.17 |
As of September 30, 2026, SynAct Pharma AB holds 3.74M in cash and equivalents against 4.02M in total debt, resulting in a net debt position of 209,987.61. Total book value stands at 12.52M, with working capital of 4.31M providing operational flexibility.
| Cash & Cash Equivalents | 3.74M |
| Total Debt | 4.02M |
| Net Debt | 209,987.61 |
| Equity (Book Value) | 12.52M |
| Book Value Per Share | 0.22 |
| Working Capital | 4.31M |
SynAct Pharma AB produced -9.72M in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | -9.72M |
| Free Cash Flow | -9.72M |
| FCF Per Share | -0.18 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -11.45: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -8.99, meaning SynAct Pharma AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -8.99 |
| FCF Yield | -11.45 |
SynAct Pharma AB's most recent stock split took place on December 16, 2024.
| Last Split Date | 12/16/2024 |
As of September 30, 2026, SynAct Pharma AB has an Altman Z-Score of -14.55, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -14.55 |
Already premium?